Drugs / Typhoid Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02415387 | Jan 2014 → Apr 2021 | depressive disorder, female breast carcinoma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01099631 | Apr 2010 → Jan 2014 | biliary tract cancer, hepatocellular carcinoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT01582321 Background | Mar 2012 → Dec 2016 | — | Queen Mary University of London | Completed | No outcome recorded |
| Phase 1 | NCT02715635 Comparator | Apr 2016 → Dec 2020 | cardiovascular disorder | Queen Mary University of London | Completed | No outcome recorded |
| Phase 4 | NCT03889158 Background | Mar 2019 → Mar 2020 | — | University of Illinois at Chicago | Terminated | No outcome recorded |
| — | NCT02628054 Comparator | Feb → Jul 2015 | — | University of Oxford | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Typhoid vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01582321 ↗ |
| Known as | Salmonella typhimurium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01099631 ↗ |
| Modality | Other / unclassified | “attenuated strain of Salmonella typhimurium expressing human interleukin-2 (IL-2)” NCT01099631 ↗ |
| Route | Oral | “will be given orally” NCT01099631 ↗ |